Dr Dhillon obtained his Bachelor of science in 1994, qualified in medicine from University College London in 1997 and obtained his PhD on cancer cell signalling from Imperial College London in 2009 funded by a CR-UK clinical training fellowship.

He is also a Consultant medical oncologist at the Royal Surrey County Hospital since 2014 treating bowel, pancreas, liver and biliary tumours.

He has previously been a Wellcome Trust clinical fellow in the University of Oxford looking at gene regulation in varying chromosomal environments and senior lecturer in oncology at Imperial College London working on cell free DNA in lung cancer.

My main research interests are in potential new treatments in bowel, liver and pancreatic cancer. We have a particular interest in immuno-oncology.

In bowel cancer we are interested in sub-types which maybe more sensitive to checkpoint inhibitor drugs. These groups include microsatellite instability- high patients (MSI-High) caused by the loss of DNA mismatch repair activity and mutations in the DNA and pathogenic variants in two proofreading DNA repair genes POLD1 and POLE. Both these groups have an ultramutated phenotype.

We have got funding from 2 drug companies for clinical trials in these groups of patients of checkpoint inhibitor drugs including common immunology translational endpoints.